CD19 and neoplasm: Production of off-the-shelf mutation-specific TCR vectors for T-cell engineering may be practical to further mitigate the adverse effects of CD19-CAR T-cell therapy by targeting tumor-specific mutations rather than the pan-B-cell marker CD19 [162].